Loading company…
Orgenesis develops cell therapies and technologies for producing advanced medicines.
Orgenesis is developing technology intended to convert a patient's liver cells into insulin-producing cells for diabetes treatment. Its POCare Platform supports the development and production of advanced medicines. Founded in 2012, the Maryland, US-based company is listed on NASDAQ under ORGS. It raised USD 10 million in venture debt from Metalmark Capital in August 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in